Daiichi Sankyo, along with Nagoya City University, Chubu University, and Mitsubishi UFJ Capital, is set to begin research on the development of a new cancer hyperthermia therapy.
Cancer hyperthermia therapy selectively kill cancer cells through heating and can be combined with radiotherapy, chemotherapy and cancer immunotherapy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The proposed cancer hyperthermia therapy seeks to achieve high safety and efficacy by specifically heating cancer cells at a constant temperature.
The newly agreed three-year partnership will be based on the results of the Take a New Challenge for Drug discovery programme, a research initiative operated by Daiichi Sankyo.
The aim of the initiative is to identify and optimise magnetic nanoparticles with a high capacity for delivery into tumours and study their practical application as a new hyperthermia therapy for cancer.
A new company named OiDE RYO-UN (RYO-UN) has been established to conduct the research.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBased in Chuo-ku, Tokyo, Japan, RYO-UN will receive funding from Mitsubishi UFJ Capital’s Open innovation for the Development of Emerging technologies fund. This is the third investment made by the fund.
Dependent on the success of the pre-agreed goals of the research, Daiichi Sankyo will buy all the stocks of RYO-UN to continue to develop the project itself.
After launching the product, Daiichi Sankyo is expected to pay considerations to Nagoya City University and Chubu University in the form of royalties.
